Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with the stock market’s minimum bid price rule.

The decision, per the company, is based on its ability to meet the continued listing requirement for market value of public shares and remaining applicable requirements except for the $1.00 minimum bid price, as well as SciSparc’s written intention statement to cure the mentioned deficiency during the second compliance period. If necessary, it will do so through a reverse stock split.

Importantly, the notification has no immediate effect on the listing or trading of SciSparc’s ordinary shares, which continue to trade under the symbol “SPRC.”


On March 8, shortly after an announcement about SciSparc’s collaboration for an Autism …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.